Bultink IE, Baden M, Lems WF (2013) Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 14(2):185–197. https://doi.org/10.1517/14656566.2013.761975

Article  CAS  PubMed  Google Scholar 

Kobza AO, Herman D, Papaioannou A, Lau AN, Adachi JD (2021) Understanding and Managing Corticosteroid-Induced Osteoporosis. Open Access Rheumatol 13:177–190. https://doi.org/10.2147/oarrr.S282606

Article  PubMed  PubMed Central  Google Scholar 

Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319–1328. https://doi.org/10.1007/s00198-007-0394-0

Article  CAS  PubMed  Google Scholar 

Hayat S, Magrey MN (2020) Glucocorticoid-induced osteoporosis: Insights for the clinician. Cleve Clin J Med 87(7):417–426. https://doi.org/10.3949/ccjm.87a.19039

Article  PubMed  Google Scholar 

Wiebe E, Huscher D, Schaumburg D, Palmowski A, Hermann S, Buttgereit T, Biesen R, Burmester GR, Palmowski Y, Boers M, Stone JH, Dejaco C, Buttgereit F (2022) Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis 81(9):1313–1322. https://doi.org/10.1136/annrheumdis-2022-222339

Article  CAS  PubMed  Google Scholar 

Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30(6):1145–1156. https://doi.org/10.1007/s00198-019-04906-x

Article  CAS  PubMed  Google Scholar 

Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102(2):274–282. https://doi.org/10.1172/jci2799

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang C, Meng H, Wang X, Zhao C, Peng J, Wang Y (2016) Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoblasts and Adipocytes and its Role in Treatment of Osteoporosis. Med Sci Monit 22:226–233. https://doi.org/10.12659/msm.897044

Article  CAS  PubMed  PubMed Central  Google Scholar 

Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61(1):7–16. https://doi.org/10.1007/s12020-018-1588-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

MacAdams MR, White RH, Chipps BE (1986) Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 104(5):648–651. https://doi.org/10.7326/0003-4819-104-5-648

Article  CAS  PubMed  Google Scholar 

Crilly R, Cawood M, Marshall DH, Nordin BE (1978) Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 71(10):733–736. https://doi.org/10.1177/014107687807101006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hahn TJ, Halstead LR, Baran DT (1981) Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52(1):111–115. https://doi.org/10.1210/jcem-52-1-111

Article  CAS  PubMed  Google Scholar 

Suzuki Y, Ichikawa Y, Saito E, Homma M (1983) Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32(2):151–156. https://doi.org/10.1016/0026-0495(83)90221-4

Article  CAS  PubMed  Google Scholar 

Rubin MR, Bilezikian JP (2002) Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87(9):4033–4041. https://doi.org/10.1210/jc.2002-012101

Article  CAS  PubMed  Google Scholar 

Weinstein RS (2010) Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone 46(3):564–570. https://doi.org/10.1016/j.bone.2009.06.030

Article  CAS  PubMed  Google Scholar 

Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, Round J, Ross EJ (1983) Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 18(2):155–166. https://doi.org/10.1111/j.1365-2265.1983.tb03198.x

Article  CAS  PubMed  Google Scholar 

Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197(1):1–10. https://doi.org/10.1677/joe-07-0606

Article  CAS  PubMed  Google Scholar 

Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27(5):1709–1718. https://doi.org/10.1007/s00198-015-3455-9

Article  CAS  PubMed  Google Scholar 

Vestergaard P (2008) Skeletal effects of systemic and topical corticosteroids. Curr Drug Saf 3(3):190–193. https://doi.org/10.2174/157488608785699487

Article  CAS  PubMed  Google Scholar 

Anastasilakis AD, Naciu AM, Yavropoulou MP, Paccou J (2023) Risk and management of osteoporosis due to inhaled, epidural, intra-articular or topical glucocorticoids. Joint Bone Spine:105604 https://doi.org/10.1016/j.jbspin.2023.105604

Mattishent K, Thavarajah M, Blanco P, Gilbert D, Wilson AM, Loke YK (2014) Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs 74(5):539–547. https://doi.org/10.1007/s40265-014-0202-z

Article  CAS  PubMed  Google Scholar 

Egeberg A, Schwarz P, Harsløf T, Andersen YMF, Pottegård A, Hallas J, Thyssen JP (2021) Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures. JAMA Dermatol 157(3):275–282. https://doi.org/10.1001/jamadermatol.2020.4968

Article  PubMed  Google Scholar 

Chi CC, Kirtschig G, Aberer W, Gabbud JP, Lipozenčić J, Kárpáti S, Haustein UF, Wojnarowska F, Zuberbier T (2017) Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. J Eur Acad Dermatol Venereol 31(5):761–773. https://doi.org/10.1111/jdv.14101

Article  PubMed  Google Scholar 

Jackson RD (2021) Topical Corticosteroids and Glucocorticoid-Induced Osteoporosis-Cumulative Dose and Duration Matter. JAMA Dermatol 157(3):269–270. https://doi.org/10.1001/jamadermatol.2020.4967

Article  PubMed  Google Scholar 

Geusens P (2008) Osteoporosis: clinical features. Minerva Med 99(2):167–175

CAS  PubMed  Google Scholar 

Li Z, Chines AA, Meredith MP (2004) Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 4(1):64–74

CAS  PubMed  Google Scholar 

Eastell R, Vittinghoff E, Lui LY, McCulloch CE, Pavo I, Chines A, Khosla S, Cauley JA, Mitlak B, Bauer DC, Bouxsein M, Black DM (2022) Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. J Bone Miner Res 37(1):29–35. https://doi.org/10.1002/jbmr.4433

Article  CAS  PubMed  Google Scholar 

Laurent MR, Goemaere S, Verroken C, Bergmann P, Body JJ, Bruyère O, Cavalier E, Rozenberg S, Lapauw B, Gielen E (2022) Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club. Front Endocrinol (Lausanne) 13:908727. https://doi.org/10.3389/fendo.2022.908727

Article  PubMed  Google Scholar 

Messina OD, Vidal M, Torres JAM, Vidal LF, Arguissain C, Pereira RM, Clark P, Cerdas Perez S, Campusano C, Lazaretti-Castro M, Zerbini C, Scali JJ, Mendez Sanchez L, Peralta-Pedrero ML, Cavallo A, Valdivia Ibarra FJ, Hernandez Pérez T (2022) Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update : This manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF). Aging Clin Exp Res 34(11):2591–2602. https://doi.org/10.1007/s40520-022-02261-2

Article  PubMed  Google Scholar 

Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–899. https://doi.org/10.1359/jbmr.040134

Article  PubMed  Google Scholar 

Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, Kohler L, Van Riel P, Vischer T, Bijlsma JW (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61(8):718–722. https://doi.org/10.1136/ard.61.8.718

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buckley L, Humphrey MB (2018) Glucocorticoid-Induced Osteoporosis. N Engl J Med 379(26):2547–2556. https://doi.org/10.1056/NEJMcp1800214

Article  PubMed  Google Scholar 

Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22(3):809–816. https://doi.org/10.1007/s00198-010-1524-7

Article  CAS  PubMed